A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...

PANAMA CITY, Fla. (WJHG/WECP) - Hope Regional Medical Center in Panama City is now using a powerful new diagnostic tool in the fight against Prostate Cancer. Doctors at the center have always used CT ...

Prostate cancer is one of the most common cancers affecting men in the United States, and it comes with a heavy price tag. Nearly 300,000 men are expected to be diagnosed this year, and treatment ...

This undated microscope image provided by the National Institutes of Health shows cancer cells with the cell nuclei stained red. The U.S. Food and Drug Administration approved the use of Paige ...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Associated Medical Professionals (A.M.P.) announced today the availability of the ArteraAI Prostate Test, an AI-powered risk stratification tool to help personalize ...

In cases of clinical equipoise, the highest MMAI score quartile could guide selective treatment intensification among patients with high-risk nonmetastatic prostate cancer. An artificial ...

It’s the second most common type of cancer among men and affects 1 in every 8 men in the United States. September is Prostate Cancer Awareness Month, and the American Cancer Society says this type of ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

GRENOBLE, France, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in prostate care, announced today passing an important ...

Advances in technology have made active surveillance in men with prostate cancer possible and prevented treatment for men who don’t need it, said Matthew Nielsen, MD, FACS, chair, Department of ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.